Supernus to Present at Cowen Healthcare Conference

Rhea-AI Summary

Supernus Pharmaceuticals (Nasdaq: SUPN) announced Jack Khattar, President and CEO, will participate in a fireside chat at the Cowen 41st Annual Health Care Conference on March 3, 2021, at 12:20 p.m. ET. A live webcast will be available on the Company's website, and an archived replay will be accessible for 60 days after the event. Supernus focuses on developing treatments for central nervous system diseases, including epilepsy and migraines, and is expanding its portfolio to address ADHD and other CNS disorders.

News Market Reaction – SUPN

-8.76%

-8.76% Session move

In the trading session that priced this news, SUPN declined 8.76%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ROCKVILLE, Md., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Cowen 41^st Annual Health Care Conference on Wednesday, March 3, 2021, at 12:20 p.m. ET.

A live webcast of the presentation can be accessed by visiting Events & Presentations in the Investor Relations section on the Company's website at www.supernus.com. An archived replay will be available for 60 days on the Company's website following the conference.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, hypomobility in Parkinson’s disease, cervical dystonia and chronic sialorrhea. We are developing a broad range of novel CNS product candidates including new potential treatments for attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s disease, epilepsy, depression, and rare CNS disorders.

For more information, please visit www.supernus.com.

CONTACTS:

Jack A. Khattar, President and CEO

Jim Kelly, EVP & Chief Financial Officer

Supernus Pharmaceuticals, Inc.

Tel: (301) 838-2591

or

INVESTOR CONTACT:

Peter Vozzo

Westwicke/ICR

Office: (443) 213-0505

Mobile: (443) 377-4767

Email: peter.vozzo@westwicke.com

FAQ

When will Supernus Pharmaceuticals participate in the Cowen Annual Health Care Conference?

Supernus Pharmaceuticals will participate in the Cowen 41^st Annual Health Care Conference on March 3, 2021, at 12:20 p.m. ET.

How can I access the live webcast of Supernus Pharmaceuticals' presentation?

The live webcast can be accessed through the Events & Presentations section in the Investor Relations area of Supernus Pharmaceuticals' website.

What is Supernus Pharmaceuticals focused on developing?

Supernus Pharmaceuticals develops products for the treatment of central nervous system diseases, including epilepsy, migraines, and ADHD.

Will there be a replay available for Supernus Pharmaceuticals' presentation?

Yes, an archived replay will be available on the Company's website for 60 days following the conference.